Business
OXB to Present at Rodman & Renshaw Conference
OXB to Present at Rodman & Renshaw Conference.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 7854P Oxford Biomedica PLC 05 September 2017 \n\n \n \n \n \n \n \nOxford BioMedica to Present at Rodman & Renshaw Annual Global Investment Conference, New York\n \nOxford, UK - 5 September 2017: Oxford BioMedica plc (\"Oxford BioMedica\" or \"the Group\") (LSE:OXB), a leading gene and cell therapy group, today announces that John Dawson, Chief Executive Officer, will be presenting at the Rodman & Renshaw Annual Global Investment Conference in New York on Tuesday 12 September at 08:20 EST. \n \n \n-Ends-\n \n \nFor further information, please contact:\nOxford BioMedica plc: Tel: +44 (0)1865 783 000\nJohn Dawson, Chief Executive Officer\nStuart Paynter, Chief Financial Officer\n \nFinancial PR Enquiries: Tel: +44 (0)20 3709 5700\nMary-Jane Elliott / Matthew Neal / Philippa Gardner / Laura Thornton\nConsilium Strategic Communications\n \n \nAbout Oxford BioMedica\nOxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the \"Group\") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, Orchard Therapeutics and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 280 people. Further information is available at www.oxfordbiomedica.co.uk.\n \n\nThis information is provided by RNSThe company news service from the London Stock Exchange END NRAQZLFBDKFFBBK\n ","length":3307,"tagName":"div"}]